Moderna's mRNA Cancer Vaccine Succeeds in Phase 3, Chinese Pharma Companies Follow in Tiered Pursuit
Nashnova编辑部
Moderna's personalized mRNA cancer vaccine proved its therapeutic value in a Phase III trial for the first time. Citi flags five Chinese drugmakers already in the race, but replicability beyond melanoma remains the central uncertainty.
What did the Phase III actually prove?
Moderna's personalized mRNA cancer vaccine delivered its first Phase III success, completing a pivotal proof-of-concept for the entire technology platform.
This means → mRNA oncology has moved from theory to the highest tier of clinical evidence — a landmark for the field.
But Citi's August 20 report is explicit: success is currently limited to melanoma alone. Whether it can be replicated across other tumor types is the core open question.
What's blocking large-scale rollout?
Citi identifies three bottlenecks: neoantigen selection — picking the right tumor targets to attack; LNP delivery efficiency — lipid nanoparticles, the microscopic "delivery capsules" that carry mRNA into cells; and personalized small-batch manufacturing.
In plain terms = every patient gets a unique vaccine. That requires rapid sequencing, rapid design, rapid production, and batch-level quality release — the opposite of traditional vaccines' "one formula, millions of doses" model.
This reflects a competitive moat built not on any single breakthrough but on end-to-end integration.
Which Chinese players are furthest ahead?
Citi favors companies with mature platforms, manufacturing infrastructure, and the ability to combine vaccines with their own immuno-oncology drugs.
Hengrui Medicine (恒瑞医药) operates through Ruihongdi, a 47%-owned subsidiary. Its RGL-270 is in Phase II — among the most advanced programs in China. In a 16-patient open-label study in post-resection pancreatic cancer, it reported 18-month relapse-free survival of 100% and a vaccine-specific immune response rate of 100%.
CSPC Pharma (石药集团) is developing SYS6026, targeting HPV16/18-related cervical lesions, also in Phase II. Unlike RGL-270, SYS6026 is a standardized viral-antigen vaccine — not patient-specific — and uses a multi-center, randomized, double-blind, placebo-controlled design, giving it a cleaner validation path.
Citi cautions: Hengrui's dataset has only 16 patients and no control arm. Conclusions require larger, controlled studies.
What are the earlier-stage players betting on?
Akeso (康方生物) has AK154, a Phase I personalized neoantigen mRNA vaccine. No human data yet, but Citi notes its proprietary bispecific antibody portfolio (cadonilimab, ivonescimab) gives it the most differentiated internal combination strategy among Chinese developers.
Everest Medicines (云顶新耀) reported first-in-human data for EVM16 (personalized): 8 of 9 patients showed neoantigen-specific T-cell responses with no dose-limiting toxicity. It is also developing EVM14, a standardized tumor-associated antigen vaccine — covering both routes in parallel.
CanSino Biologics (康希诺生物) is leveraging its mRNA process and proprietary LNP delivery for therapeutic cancer vaccines, including an early glioblastoma program, but its oncology pipeline remains at preclinical or earlier stages.
Who benefits upstream in the value chain?
The starting point for personalized mRNA cancer vaccines is genomic sequencing of tumor and normal tissue, creating upstream demand for sequencing platforms such as MGI Tech and Novogene, as well as bioinformatics service providers.
This means → if this space scales, the first to feel order growth won't be the drugmakers themselves — it will be the sequencing and data-analytics layer.
Citi's core thesis: developers that control both a vaccine platform and complementary immuno-oncology assets will be the long-term winners. In plain terms = mRNA technology alone isn't enough — you need your own immune drugs to pair with it. That platform integration capability is what sets the ceiling on valuation.
Content is for reference only, not financial advice.